Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation

Graham McIlroy; Emmanouil Nikolousis; Nervana Abou-Zeid; Paneesha Shankara; Bhuvan Kishore; Maria Kaparou; Richard Lovell; Shereef Elmoamly; David Davies; Claire Horgan; Amir Shenouda; Alexandros Kanellopoulos

doi:10.1080/10428194.2019.1650177

Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation

Graham McIlroy, Emmanouil Nikolousis, Nervana Abou-Zeid, Paneesha Shankara, Bhuvan Kishore, Maria Kaparou, Richard Lovell, Shereef Elmoamly, David Davies, Claire Horgan, Amir Shenouda, Alexandros Kanellopoulos^*

^*Corresponding author for this work

Cancer Clinical Trials Unit

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	202-205
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	61
Issue number	1
DOIs	https://doi.org/10.1080/10428194.2019.1650177
Publication status	Published - 2 Jan 2020

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428194.2019.1650177

Cite this

McIlroy, G., Nikolousis, E., Abou-Zeid, N., Shankara, P., Kishore, B., Kaparou, M., Lovell, R., Elmoamly, S., Davies, D., Horgan, C., Shenouda, A., & Kanellopoulos, A. (2020). Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma, 61(1), 202-205. https://doi.org/10.1080/10428194.2019.1650177

@article{b8586e56f02a478381af6200784b36ae,

title = "Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation",

author = "Graham McIlroy and Emmanouil Nikolousis and Nervana Abou-Zeid and Paneesha Shankara and Bhuvan Kishore and Maria Kaparou and Richard Lovell and Shereef Elmoamly and David Davies and Claire Horgan and Amir Shenouda and Alexandros Kanellopoulos",

year = "2020",

month = jan,

day = "2",

doi = "10.1080/10428194.2019.1650177",

language = "English",

volume = "61",

pages = "202--205",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor & Francis",

number = "1",

}

McIlroy, G, Nikolousis, E, Abou-Zeid, N, Shankara, P, Kishore, B, Kaparou, M, Lovell, R, Elmoamly, S, Davies, D, Horgan, C, Shenouda, A & Kanellopoulos, A 2020, 'Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation', Leukemia and Lymphoma, vol. 61, no. 1, pp. 202-205. https://doi.org/10.1080/10428194.2019.1650177

Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation. / McIlroy, Graham; Nikolousis, Emmanouil; Abou-Zeid, Nervana et al.

In: Leukemia and Lymphoma, Vol. 61, No. 1, 02.01.2020, p. 202-205.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation

AU - McIlroy, Graham

AU - Nikolousis, Emmanouil

AU - Abou-Zeid, Nervana

AU - Shankara, Paneesha

AU - Kishore, Bhuvan

AU - Kaparou, Maria

AU - Lovell, Richard

AU - Elmoamly, Shereef

AU - Davies, David

AU - Horgan, Claire

AU - Shenouda, Amir

AU - Kanellopoulos, Alexandros

PY - 2020/1/2

Y1 - 2020/1/2

UR - http://www.scopus.com/inward/record.url?scp=85070827690&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1650177

DO - 10.1080/10428194.2019.1650177

M3 - Letter

C2 - 31402762

AN - SCOPUS:85070827690

SN - 1042-8194

VL - 61

SP - 202

EP - 205

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 1

ER -

McIlroy G, Nikolousis E, Abou-Zeid N, Shankara P, Kishore B, Kaparou M et al. Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma. 2020 Jan 2;61(1):202-205. doi: 10.1080/10428194.2019.1650177